Verify any claim · lenz.io
Claim analyzed
Health“Living Cell Technologies conducted clinical trials in New Zealand in which islet cells from Auckland Island pigs were transplanted into eight patients with type 1 diabetes.”
Submitted by Silent Jaguar 017d
The conclusion
Open in workbench →The core description is accurate, but the patient count is incomplete. Reliable sources confirm that Living Cell Technologies conducted New Zealand trials transplanting Auckland Island pig islet cells into people with type 1 diabetes. However, the strongest later evidence reports 14 patients treated overall, so “eight patients” appears to describe only an early cohort, not the full New Zealand trial program.
Caveats
- The phrase “eight patients” is not the full picture; peer-reviewed reporting indicates the New Zealand program later treated 14 patients overall.
- ClinicalTrials.gov supports the sponsor, location, and intervention, but not the final exact total treated count on its own.
- Early company and trade reports can accurately describe initial cohorts while still understating later trial expansion.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
The study describes DIABECELL as neonatal porcine islets encapsulated in alginate microcapsules, and states that the trial’s purpose is to obtain safety and preliminary efficacy data in type 1 diabetic patients following transplantation of DIABECELL into the peritoneal cavity. The study location is listed as Auckland, New Zealand, and the sponsor/investigator is identified as Living Cell Technologies.
The record’s objectives are to establish the safety of xenotransplantation of DIABECELL, described as immunoprotected alginate-encapsulated porcine islets, and to assess preliminary efficacy in type 1 diabetes. The study is described as taking place in Auckland, New Zealand.
This review discusses clinical xenotransplantation experience in type 1 diabetes, including DIABECELL as an encapsulated porcine islet product used in human trials. It notes that the program involved New Zealand patients and is directly relevant to the claim about pig islet transplantation in people with type 1 diabetes.
The abstract states that Living Cell Technologies conducted clinical trials using encapsulated neonatal porcine islets in patients with type 1 diabetes. This supports the claim’s core element that the company ran human trials of pig islet xenotransplantation for type 1 diabetes.
The article describes "the first clinical trial of (alginate-encapsulated) porcine islet cell transplantation in New Zealand" conducted as an open-label phase I/IIa safety/efficacy study, with Living Cell Technologies listed in the author affiliation. It notes that "before the trial started, a multilevel testing strategy was used to screen for 26 microorganisms in donor pigs of the Auckland Island strain and the islet cell preparations used for treatment." The results section states: "Beginning in 2009, fourteen patients with severe unaware hypoglycemia were treated with one of four different dosages of alginate-encapsulated porcine islets ranging from 5000–20,000 islet equivalents delivered in a single dose."
LCT is pleased to refer you to the report from Dr John Baker, diabetes specialist conducting the DIABECELL clinical trial in New Zealand. Although only 8 candidates are required for the trial, the selection procedure is intensive. All candidates must meet the selection criteria approved by the Regional Ethics Committee and Medsafe, the regulatory authority of the Ministry of Health. A new treatment is usually first available in a country that has done clinical trials, and to date the trials have been conducted in Russia and New Zealand.
The first group of four New Zealand patients received one implant of DIABECELL at the dose of 10,000 islet equivalents per kilogram body weight (IEQ/kg)... In all patients in this group there has been a reduction in the number and severity of hypoglycaemic events. The second group of four New Zealand patients has received a dose of 15,000 IEQ/kg with no significant adverse events attributed to the treatment. DIABECELL comprises encapsulated porcine insulin-producing cells (islets) that are implanted into the abdomen of patients using a simple laparoscopic procedure.
Living Cell Technologies Limited...today announced that the New Zealand Minister of Health has approved the addition of two patients to the New Zealand Phase II clinical trial of DIABECELL. These patients will be in addition to the 12 patients already approved to receive DIABECELL implants, LCT’s encapsulated porcine islets for the treatment of Type 1 diabetes. The first four patients received one implant of DIABECELL at a dose of 10,000 islet equivalents per kilogram body weight (IEQ/kg). A second group of four patients has received a higher dose of 15,000 IEQ/kg.
The New Zealand Minister of Health has approved the addition of two patients to Living Cell Technologies' phase II clinical trial of Diabecell. The phase II trial in New Zealand is designed to evaluate Diabecell, a microencapsulated porcine islet cell therapy, in patients with unstable type 1 diabetes who experience recurrent episodes of hypoglycemia unawareness. The original trial design provided for 12 patients, in four dose-ranging cohorts of three patients each.
The release explains that Living Cell Technologies "owns a biocertified pig herd that it uses as a source of cells for treating diabetes" and that for type 1 diabetes "the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved." It states that LCT’s pigs "originate from the sub-Antarctic Auckland Islands and are disease free" and that the upgraded pig facility will "accommodate a sufficient number of pigs to support clinical trials in New Zealand and internationally over the next two years." It adds that on 19 June 2009 the New Zealand government finalized conditions for the diabetes clinical trial expected to start within two months.
In this educational video and accompanying text, Science Learning Hub describes LCT’s product: "LCT has developed a pig transplant product to treat type 1 diabetes. LCT’s DIABECELL product uses islets extracted from the pancreas of 7–16 day old piglets to produce insulin in response to blood sugar levels." It also notes that the islets are encapsulated in a seaweed-based coating to protect them from the recipient’s immune system, indicating that pig islet cell xenotransplants are being developed for clinical use in humans.
The Living Cell Technologies (LCT) DIABECELL product consists of encapsulated insulin-producing pig cells that are used to treat people with type 1 diabetes. LCT is an Auckland-based company that is developing pig cell transplants to treat diseases such as diabetes, Parkinson’s disease, Huntington’s disease, stroke and hearing loss. Pig cell transplants are currently being trialled as a treatment for type 1 diabetes, and transplanting insulin-producing pig cells into diabetics has been shown to improve blood sugar control and reduce the amount of insulin needed.
The company’s clinical summary states that DIABECELL consists of "microencapsulated porcine islets sourced from designated pathogen-free Auckland Island pigs" and is being developed for treatment of type 1 diabetes. It outlines clinical experience in which small cohorts of patients with brittle type 1 diabetes received intraperitoneal implants of these encapsulated pig islet cells in New Zealand under government approval.
This feature on LCT explains that the company uses Auckland Island pigs as a source of islet cells: "In 1986, Living Cell Technologies (LCT), acquired the company's first herd of 8 Auckland Island pigs. The company has been breeding pathogen-free pigs from this stock ever since to serve as a source of islet cells for transplant." It further states that LCT’s therapy, branded as DIABECELL, involves "encapsulated islet cells from these pigs" being transplanted into people with type 1 diabetes to provide insulin.
DIABECELL offers a promising solution for Type 1 diabetes by transplanting encapsulated pig islets into patients. DIABECELL has been tested in 38 patients across three international clinical studies to assess its safety, determine the optimal dose, and gain an early understanding of its effectiveness in managing Type 1 diabetes (NCT00940173, NCT01739829 and NCT01736228). Results indicate DIABECELL can significantly reduce unaware hypoglycemic events and allow patients to lower their insulin dosage without increasing HbA1c levels.
The report states that "scientists at the New Zealand company Living Cell Technologies have begun clinical trials today in which cells from newborn pigs will be used for the treatment of type 1 diabetes in humans." It explains that "the cells will be isolated islet cells from the pancreases of newborn pigs, which will be placed into tiny capsules and then transplanted into the abdomens of up to eight diabetic patients." The article notes that LCT’s pigs "were originally taken in the 1800s to the sub-Antarctic Auckland Islands" and have remained isolated there since.
The article recounts that pigs introduced to Auckland Island in the 19th century gave rise to a unique strain that is now used as a source for medical xenotransplantation. It notes that a New Zealand company has been using "Auckland Island pigs, which are isolated and disease-free" as donors and that their "pig islet cells could be used to treat type-1 diabetes" in humans. It describes these efforts as part of clinical trials that transplant insulin-producing cells from the Auckland Island pigs into people with diabetes.
The company’s own materials describe DIABECELL as encapsulated neonatal porcine islets and refer to clinical development for type 1 diabetes. As a primary source, this supports that Living Cell Technologies was running a pig-islet diabetes program, though the exact patient count is better established by ClinicalTrials.gov.
Although focusing on Parkinson’s disease, this article notes Living Cell Technologies’ broader xenotransplantation work with Auckland Island pigs. It states that LCT has developed cell-based therapies using tissue from Auckland Island pigs and has conducted clinical trials using encapsulated pig cells transplanted into human patients, demonstrating that LCT has experience in pig-to-human xenotransplantation across different disease indications.
Living Cell Technologies’ DIABECELL program is widely described in the medical literature and contemporaneous reporting as a New Zealand clinical trial of encapsulated porcine islet cells for type 1 diabetes. Sources commonly describe the New Zealand study as enrolling eight patients, which matches the claim’s patient count, but the exact eight-patient figure is not visible in the provided search results and should be verified against the original trial publication or company report.
This 2025 blog post discusses a newer pig islet trial in Chicago run by a different company (Otsuka), but it notes that the procedure "transplants encapsulated porcine (pig-derived) pancreatic islet cells into humans" as a treatment for unstable type 1 diabetes. It situates this work in the broader context of clinical xenotransplantation, indicating that transplanting pig islets into human T1D patients is an established clinical research approach.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
For developers
This same pipeline is available via API.
Verify your AI's output programmatically.
/extract pulls claims from text ·
/verify returns sourced verdicts ·
/ask answers follow-up questions.
Continue your research
Verify a related claim next.
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Source 7 (BioSpace, 2009) explicitly states that 'the first group of four New Zealand patients received one implant of DIABECELL' and 'the second group of four New Zealand patients has received a dose of 15,000 IEQ/kg,' confirming exactly eight patients received transplants in the initial New Zealand trial, while Source 13 (Living Cell Technologies) and Source 16 (CellMedicine.com) confirm these islets were sourced specifically from Auckland Island pigs, and Source 1 (ClinicalTrials.gov) confirms Living Cell Technologies as the sponsor conducting this trial in Auckland, New Zealand for type 1 diabetes patients.
The Proponent's argument commits cherry-picking by treating a 2009 company-facing news item (Source 7, BioSpace) describing two early cohorts of four as if it were the final treated total, while the peer‑reviewed report on the New Zealand trial states that beginning in 2009 fourteen patients were treated with alginate‑encapsulated islets from donor pigs of the Auckland Island strain (Source 5, PubMed: “Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand”). Moreover, citing ClinicalTrials.gov (Source 1; Source 2) and promotional/secondary materials (Source 13; Source 16) cannot rescue the motion's “into eight patients” specificity because those sources do not document that exactly eight patients actually received transplants, whereas Source 5 directly contradicts that number.
Argument against
The “eight patients” detail is not supported by the most authoritative trial documentation: the ClinicalTrials.gov record for LCT's Auckland, New Zealand study (NCT00940173) describes the intervention and location but does not substantiate that exactly eight patients actually received Auckland Island pig islet transplants (Source 1; Source 2). More importantly, a peer‑reviewed paper on the New Zealand trial reports that beginning in 2009 fourteen patients were treated with alginate‑encapsulated islets from the Auckland Island strain, directly contradicting the motion's specific claim of transplantation into eight patients (Source 5, PubMed: “Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand”).
The Opponent commits a temporal fallacy by citing Source 5's figure of fourteen patients — drawn from a 2014 publication covering the trial's full multi-cohort enrollment — to contradict a claim about the initial eight-patient phase, when Source 7 and Source 8 explicitly document that the first two cohorts each comprised four patients (totaling eight) before subsequent expansion was approved. Source 8 further confirms that the original twelve-patient design and later additions came after the foundational eight-patient enrollment, meaning the claim accurately describes the initial trial phase rather than the trial's total cumulative enrollment.
Expert review
3 specialized AI experts evaluated the evidence and arguments.
Expert 1 — The Logic Examiner
The logical chain for the claim's core elements — Living Cell Technologies, New Zealand, Auckland Island pigs, islet transplantation, type 1 diabetes — is robustly supported by multiple high-authority sources (Sources 1, 2, 5, 7, 8, 10, 13, 14, 16). The critical inferential dispute is over the specific patient count of 'eight.' Source 7 documents two cohorts of four patients each (totaling eight) as of August 2009, and Source 16 describes the original trial design as enrolling 'up to eight' patients. However, Source 5 (a peer-reviewed publication, the strongest direct evidence on actual enrollment) states that 'beginning in 2009, fourteen patients with severe unaware hypoglycemia were treated,' and Source 8 confirms that by December 2010 twelve patients had been approved with further additions. The proponent's rebuttal argues the claim refers to the 'initial phase,' but the claim as stated says 'conducted clinical trials in which islet cells...were transplanted into eight patients' — this is a factual assertion about total transplant recipients, not a phase-specific claim. The inference that 'eight patients' accurately describes the trial is contradicted by the best direct evidence (Source 5's fourteen patients), and the proponent's rebuttal commits a scope-narrowing fallacy by redefining 'the trial' as only its first two cohorts to rescue the specific number. The claim is therefore mostly true in its general description but misleading in its specific patient count, which the evidence directly contradicts.
Expert 2 — The Context Analyst
The claim omits that the New Zealand DIABECELL program expanded beyond the initial cohorts: contemporaneous reporting describes two early cohorts of four patients (8 total) (Source 7) and later approvals increased planned enrollment (Sources 8–9), while a peer‑reviewed paper reports that 14 patients were ultimately treated beginning in 2009 with islets from the Auckland Island strain (Source 5). With full context, it's accurate that LCT conducted NZ trials using Auckland Island pig islet transplants, but stating it was transplanted into eight patients without clarifying this refers only to an early phase gives a misleading overall impression about total treated enrollment.
Expert 3 — The Source Auditor
High-authority medical databases and peer-reviewed literature (Source 1, Source 2, and Source 5) confirm that Living Cell Technologies conducted clinical trials in New Zealand transplanting encapsulated islet cells from Auckland Island pigs into type 1 diabetes patients. While the trial eventually expanded to fourteen patients as documented in the peer-reviewed Source 5, contemporaneous trial records and company reports (Source 7, Source 8, and Source 16) verify that the initial phases of this clinical trial specifically enrolled and transplanted the first eight patients.